Chikungunya fever, a viral disease transmitted by mosquitoes, poses a significant health concern, particularly for children.

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

The initiative intends to track and prevent the spread of communicable, vector-borne, and water-borne diseases across the ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...